Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXeros Tech Regulatory News (XSG)

Share Price Information for Xeros Tech (XSG)

Share Price is delayed by 15 minutes
Get Live Data
1.45    0.05 (3.45%)
Bid:
1.40
Ask:
1.50
Spread: 0.10 (7.143%)
Market Cap: £12.93m
XSG Live PriceLast checked at - London Stock Exchange

Intraday Xeros Tech Share Chart

Directorate changes

12 Feb 2019 07:00

RNS Number : 6939P
Xeros Technology Group plc
12 February 2019
 

12 February 2019

 

Xeros Technology Group plc

 

Directorate changes

 

Xeros Technology Group plc (AIM: XSG, 'Xeros', 'the Group'), the developer and provider of water saving technologies with multiple commercial applications, today announces that John Samuel has resigned as non-executive Chairman with immediate effect. David Armfield, who joined the Board in June 2018, has been appointed interim non-executive Chairman.

 

Separately David Baynes, a director of IP Group plc, joins the Board as a non-executive director today. He is a Chartered Accountant and will Chair the Audit Committee.

David Graham Baynes, aged 55, is currently Chief Operating Officer at IP Group plc and has been on its Board since March 2014. He was previously a co-founder and the CEO of AIM-listed Fusion IP plc and was also a co-founder, CEO and CFO of Toad plc (now 21st Century Technology plc). David also worked at Celsis International plc from its incorporation to its flotation on the full list of the London Stock Exchange and was previously CFO of Codemasters Limited, at the time, the UK's largest privately-owned games company.

 

David Armfield, interim non-executive Chairman, commented:

 

"On behalf of the Board, I would like to thank John for his considerable contribution as Chairman since the business listed in March 2014. It has progressed from early stage technology development to its current position of having multiple proprietary applications in the process of commercialisation. As he steps down in order to devote more time to his other executive and non-executive Board roles - we wish him well for the future. I would also like to welcome David to the Board who brings with him a huge amount of experience in growth companies, both private and public."

 

 

Enquiries:

Xeros Technology Group plc

David Armfield, interim non-executive Chairman

Tel: 0114 321 6328

 

 

 

Jefferies International Limited (Nominated Adviser and Joint Broker)

Simon Hardy / Will Soutar

Tel: 020 7029 8000

 

 

Berenberg (Joint Broker)

Chris Bowman / Ben Wright / Laure Fine

Tel: 020 3207 7800

 

 

Instinctif Partners

Adrian Duffield / Kay Larsen / Chantal Woolcock

 

Tel: 020 7457 2020

 

AIM Rules for Companies Schedule 2 (g) information

 

David Baynes, holds or has held the following directorships in the five years preceding his appointment to the Xeros Technology Group Plc Board.

 

Current directorships:

 

 

Director, IPG USA (LP) Limited

November 2018 - Present

Director, Imperial Innovations Limited

Director, Touchstone Innovations Investments Limited

February 2018 - Present

February 2018 - Present

Director, Imperial College Company Maker Limited

February 2018 - Present

Director, Innovations Limited Partner Ltd

February 2018 - Present

Director, Touchstone Innovations Plc

December 2017 - Present

Director, IP2IPO Asia-Pacific Limited

February 2017 - Present

Director, IP2IPO US Partners Limited

December 2016 - Present

Director, IP2IPO Americas Limited

November 2016 - Present

Director, IP2IPO Carry Partner Limited

September 2016 - Present

Director, IP2IPO Portfolio (GP) Limited

September 2016 - Present

Director, Top Technology Ventures Limited

August 2015 - Present

Finance Director, IP2IPO FI Limited

September 2014 - Present

Director, Intelligent Ultrasound Group Plc

August 2014 - Present

Finance Director, IP2IPO Limited

April 2014 - Present

Finance Director, North East Technology (GP) Limited

April 2014 - Present

Finance Director, IP Venture Fund (GP) Limited

April 2014 - Present

Director, IP Group Plc

March 2014 - Present

Director, MedaPhor Limited

June 2010 - Present

Director, Morvus

September 2010 - Present

Director, Demasq Limited

April 2008 - Present

Director, Phase Focus Limited

June 2006 - Present

Director, Fusion IP Nottingham Limited

March 2008 - Present

Director, Fusion IP Two Limited

March 2008 - Present

Director, Fusion IP Cardiff Limited

November 2006 - Present

Finance Director, Biofusion Licensing (Sheffield) Limited

September 2006 - Present

Director, Fusion IP Limited

November 2004 - Present

Director, Out Of The Blue Consulting Limited

March 2003 - Present

Director, Fusion IP Sheffield Limited

January 2003 - Present

 

Previous directorships, last 5 years:

 

 

Director, Arthurian Life Sciences Limited

July 2013 - July 2015

Director, Rhedyn Limited

March 2013 - March 2016

Director, Wound Genetics Limited

November 2012 - September 2016

Director, Proflu Limited

November 2012 - July 2016

Director, Wound Genetics Therapeutics Limited

November 2012 - September 2016

Director, Wound Genetics Prognostics Limited

November 2012 - September 2016

Director, Rheometrix Microsystems Limited

April 2012 - September 2016

Director, Perlemax Limited

January 2012 - September 2014

Director, Medipex Limited

April 2011 - September 2014

Director, Mesuro Limited

September 2008 - September 2014

Director, Magnomatics Ltd

June 2008 - November 2014

Director, Biohydrogen Limited

March 2007 - September 2016

Director, Alesi Surgical Limited

March 2007 - January 2017

Director, Medella Therapeutics Limited

February 2007 - June 2014

CEO, Mantelum Limited

June 2006 - September 2016

Director, Diurnal Limited

October 2005 - October 2014

 

David Baynes was a Director of CellTran Limited, which developed a skin treatment for burns and chronic wounds using a patient's living cells but went into administration in May 2008 after running out of funds for product development and distribution.

 

There are no further disclosures to be made under Schedule 2(g) of the AIM Rules for Companies.

 

Notes to Editors

 

Xeros Technology Group plc (LN: XSG) is a platform technology company that is reinventing water intensive industrial and commercial processes.

 

Xeros' uses its patented XOrbTM technologies to significantly reduce the amount of water used in a number of major applications with the remaining water becoming far more efficient in either affixing or removing molecules from substrates such as fabrics and garments. The result being significant improvements in economic, operational and sustainability outcomes.

 

Xeros has three divisions working in the garment finishing (Textile Technologies), tanning (Tanning Technologies, branded Qualus) and cleaning/laundry (Cleaning Technologies) markets. In cleaning/laundry, the company has three applications covering domestic laundry, commercial laundry (branded "Hydrofinity") and the cleaning of high-performance workwear (branded "Marken").

 

For more information, please visit - http://www.xerostech.com/

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAFMGMZRMLGLZM
Date   Source Headline
28th Apr 20267:00 amRNSFull Year Results 2025
21st Apr 20267:00 amRNSNotice of Results and Online Presentation
5th Mar 20267:00 amRNSPurchase Order ahead of European Launch of XF3
11th Feb 202610:39 amRNSHolding(s) in Company
2nd Feb 20267:00 amRNSBoard Change
27th Jan 20267:00 amRNSTrading Update
7th Jan 20262:52 pmRNSTR-1 First Equity
2nd Jan 202611:46 amRNSBlock listing Interim Review
11th Dec 20251:06 pmRNSTR-1 Entrepreneurs Fund
2nd Dec 20254:48 pmRNSTR-1 Lombard Odier
2nd Dec 20252:26 pmRNSTR-1 Dowgate
2nd Dec 202511:10 amRNSTR-1 Maven
28th Nov 202511:02 amRNSResults of General Meeting and Director Dealings
27th Nov 202512:28 pmRNSResult of Follow-on Subscription and TVR
26th Nov 20254:44 pmRNSTR-1 Spreadex
11th Nov 20251:14 pmRNSResult of Retail Offer
7th Nov 202510:15 amRNSResult of Fundraising
7th Nov 20257:00 amRNSRetail Offer
6th Nov 20256:32 pmRNSProposed Fundraise
24th Oct 20253:07 pmRNSBlock listing Interim Review
14th Oct 20255:11 pmRNSTR-1 Maven
10th Oct 20255:20 pmRNSTR-1 Dowgate
9th Oct 20252:05 pmRNSTR-1 Spreadex
9th Oct 202511:04 amRNSTR-1 First Equity
8th Oct 20257:00 amRNSBreakthrough Launch Agreement
1st Oct 20252:08 pmRNS-RInterim Results 2025 Online Presentation
30th Sep 20257:00 amRNSInterim Results 2025
15th Sep 20256:07 pmRNSTR-1 Dowgate
12th Sep 20251:03 pmRNSTR-1 Dowgate
5th Aug 202512:13 pmRNSTR-1 First Equity
7th Jul 20252:33 pmRNSTR-1 Spreadex
19th Jun 20251:46 pmRNSResult of AGM
5th Jun 202510:11 amRNSCorrection - Application for Block Listing
4th Jun 202510:00 amRNSApplication for Block Listing
29th May 20252:43 pmRNSTR-1 Spreadex
28th May 20253:32 pmRNSTR-1 First Equity
28th May 20252:31 pmRNSTR-1 Spreadex
27th May 20252:37 pmRNSNotice of AGM and Posting of Annual Report
20th May 20257:00 amRNSFull Year Results 2024 and Trading Update
9th May 202511:08 amRNSTR-1 Spreadex
7th May 20257:00 amRNSNotice of Results and Online Presentation
6th May 202510:10 amRNSTR-1 Maven Capital
2nd May 20254:00 pmRNSTR-1 Spreadex
1st May 20254:35 pmRNSTR-1 - First Equity
31st Mar 20257:00 amRNSGrant of Options
7th Mar 202512:56 pmRNSTR-1 Spreadex
17th Feb 20252:18 pmRNSTR-1 Spreadex
17th Feb 202511:07 amRNSTR-1 First Equity
13th Feb 202512:05 pmRNSTR-1 Spreadex
13th Feb 202510:21 amRNSTR-1 First Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.